Lilly, Boehringer Ingelheim announce top-line results from empagliflozin Phase III trials on T2D

Boehringer Ingelheim and Eli Lilly and Company today announced top-line results for four completed Phase III clinical trials for empagliflozin, an investigational sodium glucose co-transporter-2 (SGLT2) inhibitor being studied for treatment of patients with Type 2 Diabetes (T2D).

Read more...
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

8 Ways to Trick Yourself Thin

8 Ways to Trick Yourself Thin An article from By Chris Freytag The formula for weight loss may be simple-take in fewer calories ...